229 related articles for article (PubMed ID: 15203129)
1. Ex vivo lymphocyte proliferative function is severely inhibited in renal transplant patients on mycophenolate mofetil treatment.
Hutchinson P; Jose M; Atkins RC; Holdsworth SR
Transpl Immunol; 2004; 13(1):55-61. PubMed ID: 15203129
[TBL] [Abstract][Full Text] [Related]
2. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolate mofetil, an inhibitor of inosine monophosphate dehydrogenase, causes a paradoxical elevation of GTP in erythrocytes of renal transplant patients.
Goldsmith D; Carrey EA; Edbury S; Smolenski RT; Jagodzinski P; Simmonds HA
Clin Sci (Lond); 2004 Jul; 107(1):63-8. PubMed ID: 14723604
[TBL] [Abstract][Full Text] [Related]
4. Immune responsiveness in renal transplant recipients: mycophenolic acid severely depresses humoral immunity in vivo.
Rentenaar RJ; van Diepen FN; Meijer RT; Surachno S; Wilmink JM; Schellekens PT; Pals ST; van Lier RA; ten Berge IJ
Kidney Int; 2002 Jul; 62(1):319-28. PubMed ID: 12081594
[TBL] [Abstract][Full Text] [Related]
5. Effect of mycophenolate mofetil in heart transplantation.
Mathieu P; Carrier M; White M; Pellerin M; Perrault L; Pelletier G; Robitaille D; Pelletier LC
Can J Surg; 2000 Jun; 43(3):202-6. PubMed ID: 10851414
[TBL] [Abstract][Full Text] [Related]
6. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF).
Allison AC; Eugui EM
Clin Transplant; 1996 Feb; 10(1 Pt 2):77-84. PubMed ID: 8680053
[TBL] [Abstract][Full Text] [Related]
7. [Use of mycophenolate mofetil in kidney transplantation].
Hrvacevic R; Ignjatovic Lj; Vavic N
Vojnosanit Pregl; 2001; 58(4):415-9. PubMed ID: 11712223
[TBL] [Abstract][Full Text] [Related]
8. Mycophenolate mofetil.
Sollinger HW
Kidney Int Suppl; 1995 Dec; 52():S14-7. PubMed ID: 8587275
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolate mofetil in pediatric renal transplantation.
Weber LT; Höcker B; Mehls O; Tönshoff B
Minerva Urol Nefrol; 2003 Mar; 55(1):91-9. PubMed ID: 12773970
[TBL] [Abstract][Full Text] [Related]
10. Effects of mycophenolate mofetil on donor-specific antibody formation in renal transplantation.
Lederer SR; Friedrich N; Banas B; Welser G; Albert ED; Sitter T
Clin Transplant; 2005 Apr; 19(2):168-74. PubMed ID: 15740551
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. The Mycophenolate Mofetil Renal Refractory Rejection Study Group.
Transplantation; 1996 Mar; 61(5):722-9. PubMed ID: 8607174
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients.
Jirasiritham S; Sumethkul V; Mavichak V; Na-Bangchang K
Transplant Proc; 2004 Sep; 36(7):2076-8. PubMed ID: 15518751
[TBL] [Abstract][Full Text] [Related]
13. Mycophenolate mofetil in pediatric renal transplantation.
Otukesh H; Sharifian M; Basiri A; Simfroosh N; Hoseini R; Sedigh N; Golnari P; Rezai M; Fereshtenejad M
Transplant Proc; 2005 Sep; 37(7):3012-5. PubMed ID: 16213289
[TBL] [Abstract][Full Text] [Related]
14. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
[TBL] [Abstract][Full Text] [Related]
15. Measurement of mycophenolate mofetil effect in transplant recipients.
Ogawa N; Nagashima N; Nakamura M; Shalabi A; Maley WR; Burdick JF
Transplantation; 2001 Aug; 72(3):422-7. PubMed ID: 11502970
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic monitoring of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable kidney-allograft recipients.
Böhler T; Canivet C; Galvani S; Therville N; Salvayre R; Negre-Salvayre A; Durand D; Thomsen M; Rostaing L; Kamar N
Int Immunopharmacol; 2008 May; 8(5):769-73. PubMed ID: 18387521
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolate mofetil: suggested guidelines for use in kidney transplantation.
Behrend M
BioDrugs; 2001; 15(1):37-53. PubMed ID: 11437674
[TBL] [Abstract][Full Text] [Related]
18. The influence of mycophenolate mofetil versus azathioprine and mycophenolic acid pharmacokinetics on the incidence of acute rejection and infectious complications after renal transplantation.
Satoh S; Tada H; Murakami M; Tsuchiya N; Inoue T; Togashi H; Matsuura S; Hayase Y; Suzuki T; Habuchi T
Transplant Proc; 2005 May; 37(4):1751-3. PubMed ID: 15919454
[TBL] [Abstract][Full Text] [Related]
19. Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.
Budde K; Glander P; Diekmann F; Dragun D; Waiser J; Fritsche L; Neumayer HH
Transplant Proc; 2004 Mar; 36(2 Suppl):524S-527S. PubMed ID: 15041401
[TBL] [Abstract][Full Text] [Related]
20. Tacrolimus/mycophenolate mofetil improved natural killer lymphocyte reconstitution one year after kidney transplant by reference to cyclosporine/azathioprine.
Vacher-Coponat H; Brunet C; Moal V; Loundou A; Bonnet E; Lyonnet L; Ravet S; Sampol-Manos E; Sampol J; Berland Y; George FD; Paul P
Transplantation; 2006 Aug; 82(4):558-66. PubMed ID: 16926601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
